MNPR earnings: a negative outcome, -5.1%

On May 9, 2024, Monopar Therapeutics reached its earnings. The result was a negative outcome, and the stock moved -5.1% in the window around the event. It had already run +34.2% in the 30 days into the catalyst — the kind of pre-event run-up that often precedes binary readouts.